The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Nanomedicines: addressing the scientific and regulatory gap
Abstract
Nanomedicine is the application of nanotechnology to the discipline of medicine: the use of nanoscale materials for the diagnosis, monitoring, control, prevention, and treatment of disease. Nanomedicine holds tremendous promise to revolutionize medicine across disciplines and specialties, but this promise has yet to be fully realized. Beyond the typical complications associated with drug development, the fundamentally different and novel physical and chemical properties of some nanomaterials compared to materials on a larger scale (i.e., their bulk counterparts) can create a unique set of opportunities as well as safety concerns, which have only begun to be explored. As the research community continues to investigate nanomedicines, their efficacy, and the associated safety issues, it is critical to work to close the scientific and regulatory gaps to assure that nanomedicine drives the next generation of biomedical innovation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Doxil® — The first FDA-approved nano-drug: Lessons learned
Barenholz, Y. (. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.03.020 · Cited by 4,792
Self-citationPharmacokinetics of Pegylated Liposomal Doxorubicin: Review of Animal and Human Studies
Gabizon, A., Shmeeda, H., & Barenholz, Y. (2003) · Clinical Pharmacokinetics · doi:10.2165/00003088-200342050-00002 · Cited by 1,634
Self-citationGabizón, A., Catane, R., Uziely, B., Kaufman, B., Safra, T., Cohen, R., Martin, F., Huang, A., & Barenholz, Y. (1994) · PubMed · Cited by 1,382
Self-citationTransport of molecules in the tumor interstitium: a review.
Jain, R. K. (1987) · PubMed · Cited by 1,378
Colloidal Gold: A Novel Nanoparticle Vector for Tumor Directed Drug Delivery
Paciotti, G. F., Myer, L., Weinreich, D., Goia, D., Pavel, N., McLaughlin, R. E., & Tamarkin, L. (2004) · Drug Delivery · doi:10.1080/10717540490433895 · Cited by 1,185
Self-citationPolymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect
Maeda, H., Bharate, G. Y., & Daruwalla, J. (2009) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2008.11.010 · Cited by 1,168
Haran, G., Cohen, R., Bar, L. K., & Barenholz, Y. (1993) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/0005-2736(93)90105-9 · Cited by 934
Self-citationProtein nanoparticles as drug carriers in clinical medicine
Hawkins, M. J., Soon-Shiong, P., & Desai, N. (2008) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.08.044 · Cited by 779
Self-citationPhase I and Pharmacokinetic Studies of CYT-6091, a Novel PEGylated Colloidal Gold-rhTNF Nanomedicine
Libutti, S. K., Paciotti, G. F., Byrnes, A. A., Alexander, H. R., Gannon, W. E., Walker, M., Seidel, G. D., Yuldasheva, N., & Tamarkin, L. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0978 · Cited by 710
Self-citationLiposome application: problems and prospects.
Barenholz, Y. (2001) · Current Opinion in Colloid & Interface Science · doi:10.1016/s1359-0294(00)00090-x · Cited by 659
Self-citationTumor microenvironment abnormalities: Causes, consequences, and strategies to normalize
Fukumura, D., & Jain, R. K. (2007) · Journal of Cellular Biochemistry · doi:10.1002/jcb.21187 · Cited by 584
Szebeni, J., Muggia, F., Gabizon, A., & Barenholz, Y. (2011) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2011.06.017 · Cited by 423
Self-citationGelation of liposome interior A novel method for drug encapsulation
Lasic, D. D., Frederik, P. M., Stuart, M. C. A., Barenholz, Y., & McIntosh, T. J. (1992) · FEBS Letters · doi:10.1016/0014-5793(92)80947-f · Cited by 261
Self-citationSzebeni, J., Bedőcs, P., Rozsnyay, Z., Weiszhár, Z., Urbanics, R., Rosivall, L., Cohen, R., Garbuzenko, O., Báthori, G., Tóth, M., et al. (2012) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2011.06.003 · Cited by 219
Self-citationClinical Pharmacology of Liposomal Anthracyclines: Focus on Pegylated Liposomal Doxorubicin
Solomon, R., & Gabizon, A. A. (2008) · Clinical Lymphoma and Myeloma · doi:10.3816/clm.2008.n.001 · Cited by 199
Ehmann, F., Sakai-Kato, K., Duncan, R., Pérez de la Ossa, D. H., Pita, R., Vidal, J.-M., Kohli, A., Tothfalusi, L., Sanh, A., Tinton, S., et al. (2013) · Nanomedicine · doi:10.2217/nnm.13.68 · Cited by 160
FDA's Approach to Regulation of Products of Nanotechnology
Hamburg, M. A. (2012) · Science · doi:10.1126/science.1205441 · Cited by 152
Gabizón, A., Chisin, R., Amselem, S., Druckmann, S., Cohen, R., Goren, D., Fromer, I. R., Peretz, T., Sulkes, A., & Barenholz, Y. (1991) · British Journal of Cancer · doi:10.1038/bjc.1991.476 · Cited by 144
Self-citationHow to Regulate Nonbiological Complex Drugs (NBCD) and Their Follow-on Versions: Points to Consider
Schellekens, H., Stegemann, S., Weinstein, V., de Vlieger, J. S. B., Flühmann, B., Mühlebach, S., Gaspar, R. S., Shah, V. P., & Crommelin, D. J. A. (2013) · The AAPS Journal · doi:10.1208/s12248-013-9533-z · Cited by 122
Self-citationIn Vitro and In Vivo Characterizations of Pegylated Liposomal Doxorubicin
Jiang, W., Lionberger, R. A., & Yu, L. X. (2011) · Bioanalysis · doi:10.4155/bio.10.204 · Cited by 113
The therapeutic equivalence of complex drugs
Schellekens, H., Klinger, E., Mühlebach, S., Brin, J., Storm, G., & Crommelin, D. J. A. (2010) · Regulatory Toxicology and Pharmacology · doi:10.1016/j.yrtph.2010.09.021 · Cited by 111
Self-citationZucker, D., Andriyanov, A. V., Steiner, A., Raviv, U., & Barenholz, Y. (2011) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.10.003 · Cited by 88
Self-citationvan Etten, B., van Geel, A. N., de Wilt, J. H. W., & Eggermont, A. M. M. (2003) · Annals of Surgical Oncology · doi:10.1245/aso.2003.03.076 · Cited by 66
Borchard, G., Flühmann, B., & Mühlebach, S. (2012) · Regulatory Toxicology and Pharmacology · doi:10.1016/j.yrtph.2012.08.009 · Cited by 66
Self-citationFarma, J. M., Puhlmann, M., Soriano, P. A., Cox, D., Paciotti, G. F., Tamarkin, L., & Alexander, H. R. (2007) · International Journal of Cancer · doi:10.1002/ijc.22270 · Cited by 62
Self-citationDifferent Pharmaceutical Products Need Similar Terminology
Crommelin, D. J. A., de Vlieger, J. S. B., Weinstein, V., et al. (2013) · The AAPS Journal · doi:10.1208/s12248-013-9532-0 · Cited by 59
FDA and Nanotech: Baby Steps Lead to Regulatory Uncertainty
Bawa, R. (2013) · Wiley eBooks · doi:10.1002/9781118451915.ch41 · Cited by 50
Self-citationCremophor EL-containing paclitaxel-induced anaphylaxis: a call to action
Irizarry, L., Luu, T. H., McKoy, J. M., Samaras, A. T., Fisher, M. J., Carias, E., Raisch, D. W., Calhoun, E. A., & Bennett, C. L. (2009) · Community Oncology · doi:10.1016/s1548-5315(11)70224-8 · Cited by 48
Pegylated liposomal doxorubicin in the management of ovarian cancer
Ferrandina, G. (2010) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s3348 · Cited by 31
Mühlebach, S., Vulto, A. G., de Vlieger, J. S. B., et al. (2013) · Generics and Biosimilars Initiative Journal · doi:10.5639/gabij.2013.0204.054 · Cited by 22
Self-citation
Cited by
Nano based drug delivery systems: recent developments and future prospects
Patra, J. K., Das, G., Fraceto, L. F., Campos, E. V. R., Rodriguez-Torres, M. D. P., Acosta-Torres, L. S., Diaz-Torres, L. A., Grillo, R., Swamy, M. K., Sharma, S., et al. (2018) · Journal of Nanobiotechnology · doi:10.1186/s12951-018-0392-8 · Cited by 6,684
Advances and Challenges of Liposome Assisted Drug Delivery
Sercombe, L., Veerati, T., Moheimani, F., Wu, S. Y., Sood, A. K., & Hua, S. (2015) · Frontiers in Pharmacology · doi:10.3389/fphar.2015.00286 · Cited by 2,632
Nanoparticle-Based Medicines: A Review of FDA-Approved Materials and Clinical Trials to Date
Bobo, D., Robinson, K. J., Islam, J., Thurecht, K. J., & Corrie, S. R. (2016) · Pharmaceutical Research · doi:10.1007/s11095-016-1958-5 · Cited by 2,586
Nanomedicine in cancer therapy: Challenges, opportunities, and clinical applications
Wicki, A., Witzigmann, D., Balasubramanian, V., & Huwyler, J. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.12.030 · Cited by 1,901
Diverse Applications of Nanomedicine
Pelaz, B., Alexiou, C., Alvarez-Puebla, R. A., Alves, F., Andrews, A. M., Ashraf, S., Balogh, L. P., Ballerini, L., Bestetti, A., Brendel, C., et al. (2017) · ACS Nano · doi:10.1021/acsnano.6b06040 · Cited by 1,350
Metadata
- Authors
- Tinkle, S., McNeil, S. E., Mühlebach, S., Bawa, R., Borchard, G., Barenholz, Y. (., Tamarkin, L., & Desai, N.
- Venue
- Annals of the New York Academy of Sciences
- Publisher
- Wiley
- Published
- 2014-03-27
- Volume
- 1313
- Issue
- 1
- Pages
- 35-56
- ISSN
- 0077-8923 (ISSN-L)
- 1749-6632
- OpenAlex
- W1567847444
- Cited by
- 546
- References
- 30
- FWCI
- 12.42
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.